AU2001284659A1 - Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists - Google Patents

Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists

Info

Publication number
AU2001284659A1
AU2001284659A1 AU2001284659A AU8465901A AU2001284659A1 AU 2001284659 A1 AU2001284659 A1 AU 2001284659A1 AU 2001284659 A AU2001284659 A AU 2001284659A AU 8465901 A AU8465901 A AU 8465901A AU 2001284659 A1 AU2001284659 A1 AU 2001284659A1
Authority
AU
Australia
Prior art keywords
methyl
phenyl
compound
oxazol
propionic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284659A
Other languages
English (en)
Inventor
Dawn Alisa Brooks
Alexander Glenn Godfrey
Sarah Beth Jones
James Ray Mccarthy
Christopher John Rito
Michael J Sayles
Leonard Larry Junior Winneroski
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001284659A1 publication Critical patent/AU2001284659A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
AU2001284659A 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists Abandoned AU2001284659A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
US60227234 2000-08-23
PCT/US2001/022616 WO2002016331A1 (fr) 2000-08-23 2001-08-23 Dérivés d'acide oxazolyl-arylpropionique et leur utilisation comme agonistes des ppar

Publications (1)

Publication Number Publication Date
AU2001284659A1 true AU2001284659A1 (en) 2002-03-04

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284659A Abandoned AU2001284659A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists

Country Status (26)

Country Link
US (2) US6930120B2 (fr)
EP (1) EP1313716B1 (fr)
JP (1) JP2004506721A (fr)
KR (1) KR20030027054A (fr)
CN (1) CN1471517A (fr)
AT (1) ATE361283T1 (fr)
AU (1) AU2001284659A1 (fr)
BR (1) BR0113409A (fr)
CA (1) CA2418104A1 (fr)
CY (1) CY1107679T1 (fr)
CZ (1) CZ2003482A3 (fr)
DE (1) DE60128239T2 (fr)
DK (1) DK1313716T3 (fr)
EA (1) EA200300286A1 (fr)
EC (1) ECSP034504A (fr)
ES (1) ES2286137T3 (fr)
HU (1) HUP0300857A3 (fr)
IL (1) IL154110A0 (fr)
MX (1) MXPA03001558A (fr)
NO (1) NO20030729L (fr)
NZ (1) NZ523804A (fr)
PL (1) PL360744A1 (fr)
PT (1) PT1313716E (fr)
SK (1) SK1872003A3 (fr)
WO (1) WO2002016331A1 (fr)
ZA (1) ZA200300570B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1313717B1 (fr) * 2000-08-23 2007-10-17 Eli Lilly And Company Derives d'acide oxazolyl-arylpropionique et leur utilisation comme agonistes des ppar
EP1313715B1 (fr) 2000-08-23 2007-08-01 Eli Lilly And Company Derives d'acide oxazolyl-aryloxyacetique et leur utilisation comme agonistes des ppar
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
ES2291688T3 (es) 2002-07-03 2008-03-01 F. Hoffmann-La Roche Ag Derivados de oxazol y su empleo como sensibilizadores a la insulina.
RU2296754C2 (ru) 2002-08-30 2007-04-10 Ф.Хоффманн-Ля Рош Аг НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPAR α И PPAR γ
BR0314261A (pt) 2002-09-12 2005-07-26 Hoffmann La Roche Compostos, processo de preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de um composto, método para tratamento e/ou profilaxia de enfermidades e utilização e/ou método de tratamento
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
MXPA05004743A (es) * 2002-11-08 2005-08-03 Hoffmann La Roche Derivados 4-alcoxioxazol sustituidos como agonistas ppar.
JP4384052B2 (ja) 2002-11-25 2009-12-16 エフ．ホフマン−ラ ロシュ アーゲー インドリル誘導体
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1658285B1 (fr) * 2003-08-20 2007-05-02 Eli Lilly And Company Composes, procedes et preparations destines a l'apport oral d'un compose peptidique de type glucagon (glp-1) ou d'un peptide agoniste du recepteur 4 de melanocortine (mc4)
ES2278346T3 (es) * 2003-08-20 2007-08-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para suministro oral de un compuesto peptido (glp)-1 del tipo de glucagon o un peptido agonista (glp)-4 del receptor 4 de melacortina (mc4).
WO2005100318A1 (fr) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Acides alcanoiques et leurs esters en tant qu'agents antidiabetiques
US20080051418A1 (en) * 2004-11-26 2008-02-28 Tsuyoshi Maekawa Arylalkanoic Acid Derivative

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
AU740444B2 (en) * 1996-08-19 2001-11-01 Japan Tobacco Inc. Propionic acid derivatives and use thereof
ATE451346T1 (de) 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
EP1313715B1 (fr) 2000-08-23 2007-08-01 Eli Lilly And Company Derives d'acide oxazolyl-aryloxyacetique et leur utilisation comme agonistes des ppar
EP1313717B1 (fr) * 2000-08-23 2007-10-17 Eli Lilly And Company Derives d'acide oxazolyl-arylpropionique et leur utilisation comme agonistes des ppar

Also Published As

Publication number Publication date
CY1107679T1 (el) 2013-04-18
ATE361283T1 (de) 2007-05-15
WO2002016331A1 (fr) 2002-02-28
NO20030729D0 (no) 2003-02-14
US20050245584A1 (en) 2005-11-03
ES2286137T3 (es) 2007-12-01
HUP0300857A3 (en) 2007-03-28
PT1313716E (pt) 2007-07-11
US7345070B2 (en) 2008-03-18
MXPA03001558A (es) 2003-06-06
KR20030027054A (ko) 2003-04-03
EP1313716B1 (fr) 2007-05-02
JP2004506721A (ja) 2004-03-04
CN1471517A (zh) 2004-01-28
NO20030729L (no) 2003-04-02
US20040097590A1 (en) 2004-05-20
DE60128239D1 (de) 2007-06-14
DE60128239T2 (de) 2008-01-10
CA2418104A1 (fr) 2002-02-28
HUP0300857A2 (hu) 2003-10-28
DK1313716T3 (da) 2007-08-27
IL154110A0 (en) 2003-07-31
EP1313716A1 (fr) 2003-05-28
ECSP034504A (es) 2003-04-25
SK1872003A3 (en) 2003-07-01
NZ523804A (en) 2004-09-24
BR0113409A (pt) 2003-07-01
ZA200300570B (en) 2004-04-21
CZ2003482A3 (cs) 2003-05-14
US6930120B2 (en) 2005-08-16
EA200300286A1 (ru) 2003-08-28
PL360744A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
US7345070B2 (en) Peroxisome proliferator activated receptor agonists
US6982278B2 (en) Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
US6417212B1 (en) Modulators of peroxisome proliferator activated receptors
US7282501B2 (en) Modulators of peroxisome proliferator activated receptors (PPAR)
EP1313717B1 (fr) Derives d'acide oxazolyl-arylpropionique et leur utilisation comme agonistes des ppar
US20080207685A1 (en) Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application